10. US Food and Drug Administration approved prescribing information. SEYSARA® (sarecycline) tablets for oral use (package insert). Almirall LLC, Exton, PA, USA. 2020.
11. Batool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proc Natl Acad Sci. 2020:202008671.
12. Batool Z, Lomakin IB, Polikanov Y, Bunick CG. 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution. J Invest Dermatol. 2020;140(7, Supp):S79.
13. Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235-1242.
14. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day Is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987-996.
15. Leyden JJ. Efficacy of benzoyl peroxide (5.3%) emollient foam and benzoyl peroxide (8%) wash in reducing Propionibacterium acnes on the back. J Drugs Dermatol. 2010;9(6):622-625.
16. Del Rosso JQ, Kircik L, Tanghetti E. Management of truncal acne vulgaris with topical dapsone 7.5% gel. J Clin Aesthet Dermatol. 2018;11(8):45-50.
17. Hoffman LK, Del Rosso JQ, Kircik LH. The efficacy and safety of azelaic acid 15% foam in the treatment of truncal acne vulgaris. J Drugs Dermatol. 2017;16(6):534-538.
18. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699.
19. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007;6(6):616-622.
20. Thompson KG, Rainer BM, Antonescu C, et al. Minocycline and its impact on microbial dysbiosis in the skin and gastrointestinal tract of acne patients. Ann Dermatol. 2020;32(1):21-30.
21. Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol. 2015;6:1543.
22. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Investig. 2014;124(10):4212-4218.
23. Nguyen LH, Örtqvist AK, Cao Y, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol. 2020;5(11):986-995.
24. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610-2616.
25. Lee TW, Russell L, Deng M, Gibson PR. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. Intern Med J. 2013;43(8):919-926.
26. Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2019;63(1).
Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials
June 2021 | Volume 20 | Issue 6 | Original Article | 634 | Copyright © June 2021
Published online May 14, 2021
James Q. Del Rosso DO,a Linda Stein Gold MD,b Hilary Baldwin MD,c Julie C. Harper MD,d Joshua Zeichner MD, e Sabine Obagi,f Emmy Graber MD MBA,g Xochitl Jimenez MD,h Francisco Hernandez Vicente,i Ayman Grada MD MHAj
aJDR Dermatology Research/Thomas Dermatology, Las Vegas, NV
bDermatology Clinical Research, Henry Ford Health System, Detroit, MI
cDepartment of Dermatology, Acne Treatment & Research Center, Morristown, NJ
dDermatology and Skin Care Center of Birmingham, Birmingham, AL
eMount Sinai Hospital, New York, NY
fBoston University School of Medicine, Boston, MA
gDermatology Institute of Boston, Boston, MA; Northeastern University, Boston, MA
hMedical Affairs, Almirall LLC., Exton, PA IGlobal Clinical Statistics, Almirall SA., Barcelona, Spain
jR&D and Medical Affairs, Almirall LLC., Exton, PA
Ayman Grada MD MHA Grada@bu.edu
